A Phase I Study of MSB2311 in Advanced Solid Tumors

NCT03463473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: 3 mg/kg Q3W MSB2311 Injection
DRUG: 10 mg/kg Q3W MSB2311 Injection
DRUG: 20 mg/kg Q3W MSB2311 Injection
DRUG: 10 mg/kg Q2W MSB2311 Injection

Sponsor

Suzhou Transcenta Therapeutics Co., Ltd.